PTUPB Compound Potentiates Cisplatin-Based-First Line Therapies with No Additional Toxicity
- 技术优势
- Orally bioavailableSignificantly reduced tumor growth compared with inhibitors selective to either pathway, alone and in combinationProlonged survival, with no additional toxicity
- 技术应用
- Cisplatin-Based-First Line TherapiesCancer
- 详细技术说明
- Cisplatin-based therapies, despite their toxicity, are used to treat most cancers due to their moderate effectiveness. Cisplatin-based-first line therapies, such as combination gemcitabine and cisplatin (GC), are often used due to higher response rates, however have associated increased toxicities. There is a need for more effective therapies that do not have higher levels of toxicity. Researchers at the University of California, Davis have discovered a compound, PTUPB, that inhibits COX-2 and sEH and protects normal tissues from cisplatin toxicity during treatment. The compound was successfully tested in patient-derived xenograft mouse models to potentiate cisplatin and GC therapies, resulting in significantly reduced tumor growth compared with inhibitors selective to either pathway, either as single agents or in combination. The models also showed prolonged survival, with no additional toxicity compared to cisplatin alone. This makes PTUPB an attractive agent for further development as a combination chemotherapy compound.
- *Abstract
-
Researchers at the University of California, Davis have discovered a compound that inhibits both cyclooxygenase-2 (COX-2) /soluble epoxide hydrolase (sEH) to improve effectiveness of chemotherapy while protecting normal tissue from cisplatin toxicity.
- *Principal Investigation
-
Name: Bruce Hammock
Department:
Name: Paul Henderson
Department:
Name: Chong Xian Pan
Department:
- 其他
-
Related Materials
Zhang, Guodong et al. “Dual Inhibition of Cyclooxygenase-2 and Soluble Epoxide Hydrolase Synergistically Suppresses Primary Tumor Growth and Metastasis.” Proceedings of the National Academy of Sciences of the United States of America 111.30 (2014): 11127–11132. doi: 10.1073/pnas.1410432111.
Wang, Fuli et al. “COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin.” Molecular Cancer Therapeutics. 17.2(2018):474-483. doi: 10.1158/1535-7163.MCT-16-0818.Additional Technologies by these Inventors
- Improved Dioxin Detection and Measurement
- Recombinant Neurotoxin: A More Effective Insecticide
- Antibodies: Urea Herbicide Pabs
- Antibodies: Triazine Herbicide Pabs
- Antibodies: Bacillus Delta Endotoxin PAbs
- Antibodies: Bromacil Herbicide PAbs
- Novel and Specific Inhibitors of p21
- Nanoparticles for Drug Delivery, Tissue Targeting and Imaging Analysis
- Beneficial Effects of Novel Inhibitors of Soluble Epoxide Hydrolase as Adjuvant Treatment for Cardiac Cell-Based Therapy
- Novel Neuropathy Treatment Using Soluble Epoxide Inhibitors
- Detection System for Small Molecules
- Methods and Compositions of Treating Diabetic Nephropathy and Insulin Resistance
- Method of Preventing Bone Loss and Periodontal Disease
- A New Pharmaceutical Therapy Target for Depression and Other Central Nervous System Diseases
- Multi-Target Inhibitors for Pain Treatment
- Antibodies for Pseudomonas (P.) aeruginosa
- Chemical Synthesis of Lipid Mediator 22-HDoHE and Structural Analogs
- Soluble Epoxide Hydrolase-Conditioned Stem Cells for Cardiac Cell-Based Therapy
- Small Molecule sEH Inhibitors to Treat Alpha-Synuclein Neurodegenerative Disorders
- Bioavailable Dual sEH/PDE4 Inhibitor for Inflammatory Pain
Tech ID/UC Case
29314/2017-956-0
Related Cases
2017-956-0
- 国家/地区
- 美国
